New hope for rare blood cancers: international trial tests smart drug cocktails
NCT ID NCT04061421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests new combinations of drugs for people with MDS/MPN, a group of rare blood cancers. The goal is to find safe and effective doses of these drug combos to better control the disease. About 94 adults will take part, receiving an oral drug called ASTX727 plus another targeted therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS/MPN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
SUSPENDEDTampa, Florida, 33612, United States
-
Oregon Health Sciences University
RECRUITINGPortland, Oregon, 97239, United States
Contact Email: •••••@•••••
-
University of Rochester Wilmot Cancer Institute
RECRUITINGRochester, New York, 14609, United States
Contact Email: •••••@•••••
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.